Skip to main content
Log in

ADAMTS13 in der Nephrologie

ADAMTS13 in nephrology

  • Nephro molekular
  • Published:
Der Nephrologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Tsai HM (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235–4244

    PubMed  CAS  Google Scholar 

  2. Furlan M, Robles R, Lammle B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223–4234

    PubMed  CAS  Google Scholar 

  3. Liu L, Choi H, Bernardo A et al (2005) Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 3:2536–2544

    Article  PubMed  CAS  Google Scholar 

  4. Bockmeyer CL, Forstmeier V, Modde F et al (2011) ADAMTS13 – marker of contractile phenotype of arterial smooth muscle cells lost in benign nephrosclerosis. Nephrol Dial Transplant 26:1871–1881

    Article  PubMed  CAS  Google Scholar 

  5. Uemura M, Tatsumi K, Matsumoto M et al (2005) Localization of ADAMTS13 to the stellate cells of human liver. Blood 106:922–924

    Article  PubMed  CAS  Google Scholar 

  6. Manea M, Tati R, Karlsson J et al (2010) Biologically active ADAMTS13 is expressed in renal tubular epithelial cells. Pediatr Nephrol 25:87–96

    Article  PubMed  Google Scholar 

  7. Budde U, Schneppenheim R (2007) Diagnostik der thrombotischen Mikroangiopathien. In: Bruhn HD, Schambeck CM, Hach-Wunderle V (Hrsg) Hämostaseologie für die Praxis. Schattauer, Stuttgart, S 91–95

  8. Hovinga JA, Studt JD, Alberio L, Lammle B (2004) von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 41:75–82

    Article  Google Scholar 

  9. Kokame K, Nobe Y, Kokubo Y et al (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93–100

    Article  PubMed  CAS  Google Scholar 

  10. Levy GG, Nichols WC, Lian EC et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494

    Article  PubMed  CAS  Google Scholar 

  11. Lotta LA, Garagiola I, Palla R et al (2010) ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 31:11–19

    Article  PubMed  CAS  Google Scholar 

  12. Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584

    Article  PubMed  CAS  Google Scholar 

  13. Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8:622–633

    Article  PubMed  CAS  Google Scholar 

  14. George JN (2009) ADAMTS13: what it does, how it works, and why it’s important. Transfusion 49:196–198

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J.U. Becker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bockmeyer, C., Modde, F. & Becker, J. ADAMTS13 in der Nephrologie. Nephrologe 8, 69–70 (2013). https://doi.org/10.1007/s11560-012-0703-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-012-0703-2

Navigation